Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 20;13(4):697.
doi: 10.3390/biom13040697.

Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study

Affiliations

Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study

Aleksandra Pełech et al. Biomolecules. .

Abstract

Gestational diabetes mellitus (GDM) is a common metabolic disease that occurs during pregnancy, with the placenta playing an important role in its pathophysiology. Currently, the role of galectin-9 in the development of GDM is unknown. The aim of this study was to compare galectin-9 concentrations in healthy pregnant women and those with GDM. Galectin-9 levels were assessed in serum samples taken both just before and after delivery, as well as in urine samples collected in the postpartum period. Maternal body composition and hydration status were evaluated using the bioelectrical impedance analysis (BIA) method. There were no statistically significant differences in the concentration of galectin-9 in women with GDM compared to healthy pregnant women in their serum samples taken just before delivery, nor in their serum and urine samples collected in the early postpartum period. However, serum galectin-9 concentrations taken before delivery were positively correlated with BMI and parameters related to the amount of adipose tissue assessed in the early postpartum period. Additionally, there was a correlation between serum galectin-9 concentrations taken before and after delivery. Galectin-9 is unlikely to become a diagnostic marker for GDM. However, this subject requires further clinical research in larger groups.

Keywords: bioelectrical impedance analysis; galectin-9; gestational diabetes mellitus; pregnancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Qualification for the study.
Figure 2
Figure 2
Spearman rank correlation coefficient = 0.545; p < 0.001.

References

    1. Hepp P., Unverdorben L., Hutter S., Kuhn C., Ditsch N., Groß E., Mahner S., Jeschke U., Knabl J., Heidegger H.H. Placental Galectin-2 Expression in Gestational Diabetes: A Systematic, Histological Analysis. Int. J. Mol. Sci. 2020;21:2404. doi: 10.3390/ijms21072404. - DOI - PMC - PubMed
    1. Modzelewski R., Stefanowicz-Rutkowska M.M., Matuszewski W., Bandurska-Stankiewicz E.M. Gestational Diabetes Mellitus—Recent Literature Review. J. Clin. Med. 2022;11:5736. doi: 10.3390/jcm11195736. - DOI - PMC - PubMed
    1. Jarmuzek P., Wielgos M., Bomba-Opon D. Placental pathologic changes in gestational diabetes mellitus. Neuroendocrinol. Lett. 2015;36:101–105. - PubMed
    1. Zhang Z., Kang X., Guo Y., Zhang J., Xie J., Shao S., Xiang Y., Chen G., Yu X. Association of circulating galectin-3 with gestational diabetes mellitus, progesterone, and insulin resistance. J. Diabetes. 2021;13:54–62. doi: 10.1111/1753-0407.13088. - DOI - PubMed
    1. Blois S.M., Gueuvoghlanian-Silva B.Y., Tirado-González I., Torloni M.R., Freitag N., Mattar R., Conrad M.L., Unverdorben L., Barrientos G., Knabl J., et al. Getting too sweet: Galectin-1 dysregulation in gestational diabetes mellitus. Mol. Hum. Reprod. 2014;20:644–649. doi: 10.1093/molehr/gau021. - DOI - PubMed

Publication types